The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet May 16th to discuss and make recommendations on the selection of strains to be included in a 2024-2025 formula for COVID-19 vaccines. As manufacturers prepare for a potential change for the 2024-2025 respiratory season, availability of current COVID-19 vaccine products is changing. Specific products will become unavailable for ordering as expiration dates near or inventory is depleted. Product availability is expected as follows:
 To manage the shorter vaccine shelf-life, we recommend providers place smaller, more frequent orders.
|